BTIG Upgrades Integra Lifesciences to Neutral
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman has upgraded Integra Lifesciences (NASDAQ:IART) from a Sell to a Neutral rating.
October 07, 2024 | 3:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Ryan Zimmerman upgraded Integra Lifesciences from Sell to Neutral, indicating a more positive outlook on the stock.
The upgrade from Sell to Neutral by BTIG suggests a more favorable view of Integra Lifesciences, which could lead to increased investor confidence and a potential positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100